AVITA MEDICAL INC (RCEL) Fundamental Analysis & Valuation

NASDAQ:RCEL • US05380C1027

Current stock price

4.47 USD
-0.15 (-3.25%)
Last:

This RCEL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. RCEL Profitability Analysis

1.1 Basic Checks

  • In the past year RCEL has reported negative net income.
  • RCEL had a negative operating cash flow in the past year.
  • In the past 5 years RCEL always reported negative net income.
  • In the past 5 years RCEL always reported negative operating cash flow.
RCEL Yearly Net Income VS EBIT VS OCF VS FCFRCEL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 2025 -20M -40M -60M

1.2 Ratios

  • The Return On Assets of RCEL (-86.16%) is worse than 70.85% of its industry peers.
Industry RankSector Rank
ROA -86.16%
ROE N/A
ROIC N/A
ROA(3y)-65.15%
ROA(5y)-48.75%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RCEL Yearly ROA, ROE, ROICRCEL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 2025 0 500 -500 -1K

1.3 Margins

  • Looking at the Gross Margin, with a value of 83.27%, RCEL belongs to the top of the industry, outperforming 86.68% of the companies in the same industry.
  • RCEL's Gross Margin has been stable in the last couple of years.
  • RCEL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 83.27%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.12%
GM growth 5Y0.47%
RCEL Yearly Profit, Operating, Gross MarginsRCEL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 2025 0 -100 -200

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. RCEL Health Analysis

2.1 Basic Checks

  • RCEL does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • RCEL has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, RCEL has more shares outstanding
  • RCEL has a worse debt/assets ratio than last year.
RCEL Yearly Shares OutstandingRCEL Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 10M 20M 30M
RCEL Yearly Total Debt VS Total AssetsRCEL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

2.2 Solvency

  • RCEL has an Altman-Z score of -10.69. This is a bad value and indicates that RCEL is not financially healthy and even has some risk of bankruptcy.
  • RCEL has a worse Altman-Z score (-10.69) than 74.52% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -10.69
ROIC/WACCN/A
WACC9.46%
RCEL Yearly LT Debt VS Equity VS FCFRCEL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 2025 0 50M -50M 100M

2.3 Liquidity

  • RCEL has a Current Ratio of 0.57. This is a bad value and indicates that RCEL is not financially healthy enough and could expect problems in meeting its short term obligations.
  • With a Current ratio value of 0.57, RCEL is not doing good in the industry: 89.96% of the companies in the same industry are doing better.
  • RCEL has a Quick Ratio of 0.57. This is a bad value and indicates that RCEL is not financially healthy enough and could expect problems in meeting its short term obligations.
  • RCEL has a worse Quick ratio (0.46) than 90.35% of its industry peers.
Industry RankSector Rank
Current Ratio 0.57
Quick Ratio 0.46
RCEL Yearly Current Assets VS Current LiabilitesRCEL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. RCEL Growth Analysis

3.1 Past

  • RCEL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 26.78%, which is quite impressive.
  • The Revenue has grown by 11.45% in the past year. This is quite good.
  • RCEL shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 38.09% yearly.
EPS 1Y (TTM)26.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.64%
Revenue 1Y (TTM)11.45%
Revenue growth 3Y27.66%
Revenue growth 5Y38.09%
Sales Q2Q%-4.29%

3.2 Future

  • RCEL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 32.69% yearly.
  • RCEL is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 36.14% yearly.
EPS Next Y55.02%
EPS Next 2Y26.82%
EPS Next 3Y38.68%
EPS Next 5Y32.69%
Revenue Next Year19.9%
Revenue Next 2Y33.92%
Revenue Next 3Y47.36%
Revenue Next 5Y36.14%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
RCEL Yearly Revenue VS EstimatesRCEL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M 400M 500M
RCEL Yearly EPS VS EstimatesRCEL Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4 6

More info and screens

Find the best growth stocksShow best growing peers

1

4. RCEL Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for RCEL. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RCEL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RCEL Price Earnings VS Forward Price EarningsRCEL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RCEL Per share dataRCEL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as RCEL's earnings are expected to grow with 38.68% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.82%
EPS Next 3Y38.68%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. RCEL Dividend Analysis

5.1 Amount

  • RCEL does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

RCEL Fundamentals: All Metrics, Ratios and Statistics

AVITA MEDICAL INC

NASDAQ:RCEL (3/17/2026, 2:33:03 PM)

4.47

-0.15 (-3.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)01-13
Earnings (Next)05-06
Inst Owners15.86%
Inst Owner Change-5.28%
Ins Owners1.37%
Ins Owner Change19.51%
Market Cap136.92M
Revenue(TTM)71.61M
Net Income(TTM)-48.59M
Analysts80
Price Target6.32 (41.39%)
Short Float %12.63%
Short Ratio16.72
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-34.84%
Min EPS beat(2)-58.8%
Max EPS beat(2)-10.88%
EPS beat(4)0
Avg EPS beat(4)-38.71%
Min EPS beat(4)-58.8%
Max EPS beat(4)-10.88%
EPS beat(8)1
Avg EPS beat(8)-32.32%
EPS beat(12)3
Avg EPS beat(12)-22.95%
EPS beat(16)7
Avg EPS beat(16)-10.85%
Revenue beat(2)0
Avg Revenue beat(2)-4.57%
Min Revenue beat(2)-8.01%
Max Revenue beat(2)-1.13%
Revenue beat(4)0
Avg Revenue beat(4)-10.85%
Min Revenue beat(4)-20.13%
Max Revenue beat(4)-1.13%
Revenue beat(8)1
Avg Revenue beat(8)-7.42%
Revenue beat(12)4
Avg Revenue beat(12)-5.12%
Revenue beat(16)8
Avg Revenue beat(16)-0.27%
PT rev (1m)0%
PT rev (3m)-10.14%
EPS NQ rev (1m)4.54%
EPS NQ rev (3m)4.54%
EPS NY rev (1m)10.62%
EPS NY rev (3m)6.27%
Revenue NQ rev (1m)-6.79%
Revenue NQ rev (3m)-6.47%
Revenue NY rev (1m)-0.19%
Revenue NY rev (3m)-6.01%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.91
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.75
EYN/A
EPS(NY)-0.79
Fwd EYN/A
FCF(TTM)-1.07
FCFYN/A
OCF(TTM)-1.02
OCFYN/A
SpS2.34
BVpS-0.54
TBVpS-0.73
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -86.16%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 83.27%
FCFM N/A
ROA(3y)-65.15%
ROA(5y)-48.75%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.12%
GM growth 5Y0.47%
F-Score3
Asset Turnover1.27
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 69.88%
Cap/Sales 2.29%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.57
Quick Ratio 0.46
Altman-Z -10.69
F-Score3
WACC9.46%
ROIC/WACCN/A
Cap/Depr(3y)367.62%
Cap/Depr(5y)268.86%
Cap/Sales(3y)6.44%
Cap/Sales(5y)4.93%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)26.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.64%
EPS Next Y55.02%
EPS Next 2Y26.82%
EPS Next 3Y38.68%
EPS Next 5Y32.69%
Revenue 1Y (TTM)11.45%
Revenue growth 3Y27.66%
Revenue growth 5Y38.09%
Sales Q2Q%-4.29%
Revenue Next Year19.9%
Revenue Next 2Y33.92%
Revenue Next 3Y47.36%
Revenue Next 5Y36.14%
EBIT growth 1Y26.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year55.65%
EBIT Next 3Y35.15%
EBIT Next 5Y24.79%
FCF growth 1Y43.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y36.26%
OCF growth 3YN/A
OCF growth 5YN/A

AVITA MEDICAL INC / RCEL Fundamental Analysis FAQ

What is the ChartMill fundamental rating of AVITA MEDICAL INC (RCEL) stock?

ChartMill assigns a fundamental rating of 2 / 10 to RCEL.


What is the valuation status of AVITA MEDICAL INC (RCEL) stock?

ChartMill assigns a valuation rating of 1 / 10 to AVITA MEDICAL INC (RCEL). This can be considered as Overvalued.


Can you provide the profitability details for AVITA MEDICAL INC?

AVITA MEDICAL INC (RCEL) has a profitability rating of 1 / 10.